Day: December 1, 2022

VANCOUVER, British Columbia, Dec. 01, 2022 (GLOBE NEWSWIRE) — Pulse Oil Corp., (“Pulse” or the “Company”) (TSXV: PUL) is pleased to announce that the Company has filed its Q3 2022 unaudited interim financial statements and management discussion and analysis for the three-month period ending September 30, 2022. Quarterly Financials for September 30, 2022 (CDN$): Some of the financial highlights of the third quarter results are provided as well as second quarter results of 2022 and the comparable results for the three-month period last year are as follows:Description September 30, 2022 June 30, 2022 September 30, 2021Gross Revenue $1,596,147 $1,585,097 $934,580Net income $322,694 $574,523 $28,133Cashflow from operations $797,649 $(134,901) $482,841Production details:Oil (Bbl/d)Gas (Mcf/d)NGL (Bbl/d)Total (Boe/d) 140.0541.426.7259.8 149.1423.324.8244.4 121.4396.618.4205.9Pricing...

SANTA CLARA, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI vision silicon company, today announced financial results for its third quarter of fiscal year 2023 ended October 31, 2022.Revenue for the third quarter of fiscal 2023 was $83.1 million, down 10% from $92.2 million in the same period in fiscal 2022. For the nine months ended October 31, 2022, revenue was $254.3 million, up 5% from $241.6 million for the nine months ended October 31, 2021. Gross margin under U.S. generally accepted accounting principles (GAAP) for the third quarter of fiscal 2023 was 62.2%, compared with 62.5% for the same period in fiscal 2022. For the nine months ended October 31, 2022, GAAP gross margin was 62.6%, compared with 62.4% for the nine months ended October 31, 2021. GAAP net loss for the third quarter...

LYNNWOOD, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the third quarter ended October 29, 2022. Net sales for the third quarter ended October 29, 2022 (13 weeks) decreased 17.9% to $237.6 million from $289.5 million in the third quarter ended October 30, 2021 (13 weeks). Net income in the third quarter of fiscal 2022 was $6.9 million, or $0.36 per diluted share, compared to net income of $30.7 million, or $1.25 per diluted share, in the third quarter of the prior fiscal year. Total net sales for the nine months (39 weeks) ended October 29, 2022 decreased 19.0% to $678.3 million from $837.2 million reported for the nine months (39 weeks) ended October 30, 2021. Net income for the...

First Quarter HighlightsRevenue grows 54% year-over-year to $355.5 million Calculated billings grows 37% year-over-year to $340.1 million Deferred revenue grows 55% year-over-year to $1,005.7 million GAAP net loss of $68.2 million compared to GAAP net loss of $90.8 million on a year-over-year basis Non-GAAP net income of $44.0 million compared to non-GAAP net income of $21.0 million on a year-over-year basisSAN JOSE, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its first quarter of fiscal year 2023, ended October 31, 2022. “We delivered strong top line growth with improved operating profitability and increased free cash flow, once again performing at the Rule-of-80. We are seeing customers committing to our broader platform,...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel therapies for women’s health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “We are pleased to have neared the completion of a restructuring process that allowed us to generate an important influx of capital, positioned us to resolve our over-indebted position, and streamlined our cost structure,” said Brian O’Callaghan, CEO of ObsEva. “We are now well-positioned to support the development of nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization,...